CompletedPhase 2NCT00554515

The High-Dose Aldesleukin (IL-2) "Select" Trial for Patients With Metastatic Renal Cell Carcinoma

Studying Clear cell renal carcinoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Beth Israel Deaconess Medical Center
Principal Investigator
David F McDermott, MD
Beth Israel Deaconess Medical Center
Intervention
HD IL2(drug)
Enrollment
123 target
Eligibility
18-80 years · All sexes
Timeline
2006 – 2013

Study locations (1)

Collaborators

City of Hope National Medical Center · Providence Cancer Center, Earle A. Chiles Research Institute · Dartmouth-Hitchcock Medical Center · Indiana University · Loyola University · Our Lady of Mercy Medical Center · Roswell Park Cancer Institute · University of California, Los Angeles · University of Cincinnati · University of Pittsburgh · University of Virginia · Vanderbilt University · Wayne State University · Dana-Farber Cancer Institute

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00554515 on ClinicalTrials.gov

Other trials for Clear cell renal carcinoma

Additional recruiting or active studies for the same condition.

See all trials for Clear cell renal carcinoma →

← Back to all trials